Tag Archives: oncology

At the beginning of February, we published this article on Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX), noting the upside momentum seen during the period running up to our coverage, and attempting to ascertain whether this action was a one-off...

TapImmune Inc (NASDAQ:TPIV) has been a pretty tough stock to hold over the last year or so, with the company having declined from a little over seven dollars a share to current levels around four dollars a piece. Against the backdrop of share...

Immunomedics, Inc. (NASDAQ:IMMU) has been on our watch list for a while. The company is a development stage biotechnology entity working to develop a range of cancer treatments, and our long-term bull thesis was rooted in the fact that it was...

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) is up more than 25% on its February open on its highest volume since mid last year. The gains come on the back of no real fundamental developments, but management has been doing the presentation rounds,...

Immune Pharmaceuticals Inc (NASDAQ:IMNP) just announced that it has appointed a new chairman of its board of directors, but the company has remained relatively flat on the release. Markets seem to have overlooked the appointment, not just from...

Cellectar Biosciences Inc (NASDAQ:CLRB) just announced that it has had an additional patent granted by the United States Patent and Trademark Office (USPTO) relating to the its two lead assets, CLR 131 and CLR 125. The release was relatively...

Earlier this month, we highlighted Immune Pharmaceuticals Inc (NASDAQ:IMNP) as a potential biotechnology exposure, and asked ourselves the question, is there any value in a holding? Our conclusion was as follows: there is value there, so long...

In July last year, we highlighted OXIS International, Inc. (OTCMKTS:OXIS) as being a company keep an eye on. At the time, the company had just signed a deal with the University of Minnesota that would see the two partner up on a new type of...

Heat Biologics Inc (NASDAQ:HTBX) struggled during the final quarter of 2016, as the company put out disappointing results from its lead bladder cancer trial. Sentiment remained pretty negative towards the close of the year, but as 2017 has...

We’re always on the lookout for biotech runners, and one that’s impossible to overlook right now is Transgenomic Inc (NASDAQ:TBIO). The company gained close to 300% on Thursday, and looks set to continue its run into the end of...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter